State Street Corp Trevena Inc Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	SELL	$0.16 - $100.0 $1,027 - $642,100	-6,421 Reduced 1.02%	621,642 $95,000
Q2 2022 Aug 15, 2022	SELL	$0.2 - $0.5 $423,462 - $1.06 Million	-2,117,313 Reduced 77.12%	628,063 $260,000
Q1 2022 May 16, 2022	SELL	$0.41 - $0.63 $22,182 - $34,084	-54,103 Reduced 1.93%	2,745,376 $1.51 Million
Q4 2021 Feb 14, 2022	BUY	$0.57 - $1.29 $625 - $1,415	1,097 Added 0.04%	2,799,479 $1.63 Million
Q3 2021 Nov 15, 2021	BUY	$1.11 - $1.7 $148,683 - $227,713	133,949 Added 5.03%	2,798,382 $3.44 Million
Q2 2021 Aug 16, 2021	BUY	$1.46 - $2.25 $3.76 Million - $5.8 Million	2,577,702 Added 2972.07%	2,664,433 $4.5 Million
Q4 2020 Feb 16, 2021	SELL	$2.13 - $3.26 $26,838 - $41,076	-12,600 Reduced 12.68%	86,731 $186,000
Q3 2020 Nov 10, 2020	BUY	$1.53 - $3.13 $74,205 - $151,805	48,500 Added 95.41%	99,331 $297,000
Q2 2020 Aug 14, 2020	BUY	$0.48 - $1.75 $12,624 - $46,025	26,300 Added 107.21%	50,831 $76,000
Q1 2020 May 11, 2020	BUY	$0.56 - $0.97 $13,737 - $23,795	24,531 New	24,531 $14,000

Ticker TRVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 173,680,992
Market Cap $650M
Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.